RedHill Biopharma presents positive Phase 2 data for oral opaganib in hospitalized patients with COVID-19 at World Microbe ForumProactive Investors • 06/22/21
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19PRNewsWire • 06/21/21
RedHill completes enrollment in the global Phase 2/3 severe COVID-19 study with oral opaganibProactive Investors • 06/08/21
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 StudyPRNewsWire • 06/07/21
RedHill Biopharma highlights strong end to first-quarter and almost 100% enrollment in opaganib's Phase 2/3 study for COVID-19Proactive Investors • 06/01/21
RedHill Biopharma Ltd.'s (RDHL) CEO Dror Ben-Asher on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/27/21
Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?Zacks Investment Research • 05/27/21
RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 05/27/21
RedHill Biopharma receives two US Patent and Trademark Office Allowances for its oral pills for COVID-19, opaganib and RHB-10Proactive Investors • 05/26/21
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19PRNewsWire • 05/26/21
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021PRNewsWire • 05/24/21
RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021PRNewsWire • 05/21/21
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021PRNewsWire • 05/20/21
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to ContinuePRNewsWire • 04/09/21
RedHill Biopharma announces resolution to patent litigation in the US in response to a generic version of MovantikProactive Investors • 03/26/21
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN PharmaceuticalsPRNewsWire • 03/25/21
RedHill Biopharma provides opaganib treatment under compassionate use exemption for several Swiss patients suffering from coronavirus pneumoniaProactive Investors • 03/22/21
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in SwitzerlandPRNewsWire • 03/22/21